Clinical trials: Non-Valvular Atrial Fibrillation
Non-valvular Atrial Fibrillation
An Early Feasibility Study Evaluating the Safety and Efficacy of the Laminar Left Atrial Appendage Closure System in Subjects With Non-Valvular Atrial Fibrillation
This is an early feasibility study is to evaluate the safety and effectiveness of the Laminar Left Atrial Appendage Closure System to treat patients with non-valvular atrial fibrillation that cannot take, or a have a reason to…
- Trial name
- NCT05565599
- Testing
- Left Atrial Appendage Closure
- Where
- 7 sites in United States
- Volunteers
- 58 people
- Sponsor
- Jaguar LAA, Inc.
Non-valvular Atrial Fibrillation, Stroke
A Pivotal Investigational Device Exemption Study on Laminar Left Atrial Appendage Elimination
The purpose of this study is to compare the safety and effectiveness of Laminar Left Atrial Appendage Closure (LAAC) device as compared to the commercially available LAAC devices in participants with non-valvular atrial…
- Conditions
- Non-valvular Atrial Fibrillation, Stroke, Systemic Embolism
- Trial name
- NCT06168942
- Testing
- Experimental: Laminar Left Atrial Appendage Closure System, Active Comparator: WATCHMAN / Amulet
- Where
- 36 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- Jaguar LAA, Inc.
Non-valvular Atrial Fibrillation (AF)
Vortosiran in Atrial Fibrillation
This is a randomised, actively controlled Phase IIb trial to evaluate the safety and pharmacodynamics (PD) of two blinded doses of subcutaneously administered vortosiran and open-label apixaban in patients with AF.
- Trial name
- NCT07870889
- Testing
- Vortosiran, Apixaban
- Where
- 15 sites in Denmark, Norway and 2 more
- Volunteers
- 150 people
- Sponsor
- Ribocure Pharmaceuticals AB
Non-valvular Atrial Fibrillation (AF), Left Atrial Appendage Closure
WATCHMAN FLX Pro European Registry
The WATCHMAN FLX Pro European registry is intended to gather real world clinical data for patients undergoing left atrial appendage closure (LAAC) with the WATCHMAN FLX™ Pro device.
- Trial name
- NCT07262255
- Testing
- Left atrial appendage closure
- Where
- 20 sites in Denmark, Germany and 4 more
- Volunteers
- 189 people
- Sponsor
- Boston Scientific Corporation
Non Valvular Atrial Fibrillation
Append Prague Study
This study is intended to evaluate the safety and feasibility of the Append System for left atrial appendage (LAA) elimination using a transcatheter procedure that invaginates and ligates the LAA tissue.
- Trial name
- NCT07816029
- Testing
- Append System
- Where
- Czechia
- Volunteers
- 75 people
- Sponsor
- Append Medical Ltd.
Non-Valvular Atrial Fibrillation
Amplatzer Amulet China Post Market Study (PMS)
The purpose of this study is to prospectively evaluate the safety and effectiveness of the Amplatzer Amulet LAA occluder in a Chinese patient population indicated for use of this device.
- Trial name
- NCT06189365
- Testing
- Left Atrial Appendage (LAA) closure procedure with Amplatzer Amulet LAA occluder
- Where
- 5 sites in China
- Volunteers
- 50 people
- Sponsor
- Abbott Medical Devices
Non-valvular Atrial Fibrillation (NVAF)
FIM Study of the LAmbre™ II LAA Occluder in Non-Valvular AF Patients
To evaluate the preliminary safety and feasibility of the LAmbreTM II Left Atrial Appendage Occluder and the Occluder Delivery System in patients with non-valvular atrial fibrillation who are at increased risk for stroke and…
- Trial name
- NCT07385599
- Testing
- LAmbre™ II Left Atrial Appendage Occluder and Occluder Delivery System
- Where
- Hong Kong
- Volunteers
- 10 people
- Sponsor
- Lifetech Scientific (Shenzhen) Co., Ltd.
Non-Valvular Atrial Fibrillation (NVAF)
A Study Evaluating the Associations Between Clinical Characteristics and Use of Oral Anticoagulants in Italian Elderly Participants With Non-Valvular Atrial Fibrillation
The purpose of this study is to provide real-world data useful to address the factors associated to the administration of oral anticoagulants in the elderly population affected by non-valvular atrial fibrillation (NVAF), in…
- Trial name
- PRESBUS (NCT05232643)
- Where
- Italy
- Volunteers
- 636 people
- Sponsor
- Bristol-Myers Squibb
Non Valvular Atrial Fibrillation
Applause Study I - Append System Early Feasibility Study
This early feasibility study is intended to evaluate the safety and feasibility of the Append System for eliminating the left atrial appendage (LAA) through a transcatheter procedure that invaginates and ligates the LAA tissue.
- Trial name
- Applause (NCT07278869)
- Testing
- Left Atrial Appendage Elimination: Append System
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- Append Medical Ltd.
Non-valvular Atrial Fibrillation
The CONFORMAL Early Feasibility Study
An evaluation of the safety and performance of the Conformal Left Atrial Appendage Seal for Left Atrial Appendage Occlusion
- Trial name
- NCT03616028
- Testing
- left atrial appendage closure
- Where
- 11 sites in United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Conformal Medical, Inc
Non-valvular Atrial Fibrillation (AF)
Watchman FLX Pro CT Pilot Study
The primary objective of this study is to measure device tissue coverage post-implantation of the WATCHMAN FLX™ Pro Left Atrial Appendage Closure (LAAC) Device (WATCHMAN FLX Pro) using the serial advanced imaging modalities of…
- Trial name
- NCT05567172
- Testing
- Left atrial appendage closure device WM FLX Pro
- Where
- Denmark
- Volunteers
- 43 people
- Sponsor
- Boston Scientific Corporation
Non-Valvular Atrial Fibrillation
Evaluation of Safety and Performance of the Omega™ LAA (Left Atrial Appendage) Occluder and Omega™ Delivery System in Patients With Non-Valvular Atrial Fibrillation and High Bleeding Risk
The purpose of the study is to assess the safety and performance of the Omega™ LAA (Left Atrial Appendage) Occluder and Omega™ Delivery System in LAA (Left Atrial Appendage) closure for patients with non-valvular atrial…
- Trial name
- Omega (NCT04829929)
- Testing
- Omega™LAA Occluder implantation
- Where
- 13 sites in Denmark, Germany and 4 more
- Volunteers
- 200 people
- Sponsor
- Eclipse Medical Ltd.
The Focus of the Study is to Reduce the Risk of Stroke and Life-threatening Bleeding Events in Patients With Non-valvular Atrial Fibrillation
WATCHMAN FLX™ CT Study
WATCHMAN FLX™ CT is a prospective, single-arm, single-center, post-market investigation to assess device tissue coverage in subjects with non-valvular atrial fibrillation (AF) who receive the WATCHMAN FLX device to reduce the…
- Trial name
- NCT05324371
- Testing
- Watchman FLX Device
- Where
- Denmark
- Volunteers
- 25 people
- Sponsor
- Boston Scientific Corporation
Non-Valvular Atrial Fibrillation
Clinical and Economic Outcomes of Oral Anticoagulants in Non-valvular Atrial Fibrillation
The primary objectives of this study are to compare the risk of major bleeding and stroke/systemic embolism (SE) events among oral anticoagulant (OAC)-naïve non-valvular atrial fibrillation (NVAF) patients initiating OAC warfarin…
- Trial name
- ARISTOPHANES (NCT03087487)
- Where
- United States
- Volunteers
- 466,991 people
- Sponsor
- Bristol-Myers Squibb
Non Valvular Atrial Fibrillation
Apixaban Versus Rivaroxaban in Non Valvular Atrial Fibrillation
The investigators will first measure the maximum concentration (after 2 hours of intake) and the residual concentration (just before the next intake) after at least 15 consecutive days of treatment.
- Trial name
- APIXA-Xa (NCT06862726)
- Testing
- Anti Xa dosage, Dosage of PT-INR
- Where
- Tunisia
- Volunteers
- 120 people
- Sponsor
- Les Laboratoires des Médicaments Stériles
Non-valvular Atrial Fibrillation
Real-world Study on Edoxaban Treatment for Patients With Non-valvular Atrial Fibrillation in China
The safety of edoxaban treatment will be examined using real-world clinical evidence from adult patients with non-valvular atrial fibrillation (NVAF) indications in routine clinical practice.
- Trial name
- ETNA-AF-CHINA (NCT04747496)
- Testing
- Edoxaban
- Where
- 97 sites in China
- Volunteers
- 5,000 people
- Sponsor
- Daiichi Sankyo
Non-valvular Atrial Fibrillation (NVAF)
A Study to Evaluate the Safety and Effectiveness of Rivaroxaban (Xarelto) for Prevention of Stroke and Systemic Embolism in Indian Patients With Non-valvular Atrial Fibrillation (NVAF)
This study is planned to collect prospective data and evaluate the safety and effectiveness of rivaroxaban for the prevention of stroke and systemic embolism in Indian patients with NVAF when used in clinical practice under…
- Trial name
- XARIN (NCT03887780)
- Testing
- Rivaroxaban (Xarelto,Bay 59-7939)
- Where
- India
- Volunteers
- 504 people
- Sponsor
- Bayer
Non-valvular Atrial Fibrillation (NVAF)
To Compare the Pharmacokinetics and Safety After a Single Dose Administration of IN-G00002 and IN-R00002 in Healthy Adult Volunteers
To compare the pharmacokinetics and safety after a single dose administration of IN-G00002 and IN-R00002 in healthy adult volunteers
- Trial name
- NCT06725355
- Testing
- IN-R00002, IN-G00002
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- HK inno.N Corporation
Non-valvular Atrial Fibrillation
Study Aims to Collect Information in Routine Clinical Practice in Italy About the Number of Patients Suffering From Irregularly Heart Beats Which Are Not Caused by a Heart Valve Problem (Non-valvular Atrial Fibrillation, NVAF) Who Stopped or Changed Rivaroxaban Treatment
While it is well known that stopping or changing medication with blood thinners in patients who suffer from non-valvular atrial fibrillation (NVAF) increases the risk of ischemic stroke (a condition which occurs when a vessel…
- Trial name
- RITMUS-AF (NCT04174859)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- Italy
- Volunteers
- 812 people
- Sponsor
- Bayer
Non-valvular Atrial Fibrillation
The Conformal Prague Study
A prospective, single center, open-label, single arm, study to evaluate the safety and technical performance of the CLAAS system for closure of the left atrial appendage.
- Trial name
- NCT04193826
- Testing
- Left Atrial Appendage Closure
- Where
- Czechia
- Volunteers
- 20 people
- Sponsor
- Conformal Medical, Inc